<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Anaplastic thyroid cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Anaplastic thyroid cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Anaplastic thyroid cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            R Michael Tuttle, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric J Sherman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David S Cooper, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas S Ross, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jean E Mulder, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anaplastic thyroid cancers are undifferentiated tumors of the thyroid follicular epithelium. In marked contrast to differentiated thyroid cancers, anaplastic cancers are extremely aggressive, with a disease-specific mortality approaching 100 percent. Given the very rapid course of disease progression and the poor treatment outcomes, end-of-life issues and plans for comfort care measures are an integral part of initial disease management planning [
         <a href="#rid1">
          1
         </a>
         ]. Early recognition of the disease is essential to allow prompt initiation of therapy.
        </p>
        <p>
         The major clinical issues related to anaplastic thyroid cancer will be reviewed here. The molecular pathogenesis of this disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7819.html" rel="external">
          "Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The age-adjusted annual incidence of anaplastic cancer is approximately one to two per million persons [
         <a href="#rid2">
          2,3
         </a>
         ] and accounts for 0.9 to 9.8 percent of all thyroid cancers globally [
         <a href="#rid4">
          4,5
         </a>
         ]. Patients with anaplastic cancer are older than those with differentiated cancer; the mean age at diagnosis is 65 years, and fewer than 10 percent are younger than 50 years. Sixty to 70 percent of tumors occur in women [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2187194">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H764044138">
         <span class="h2">
          Antecedent thyroid disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 20 percent of patients with anaplastic thyroid cancer have a history of differentiated thyroid cancer, and 20 to 30 percent have a coexisting differentiated cancer [
         <a href="#rid8">
          8-12
         </a>
         ]; the percentage may be even higher with extensive sectioning of the thyroid gland [
         <a href="#rid13">
          13
         </a>
         ]. The majority of synchronous thyroid tumors are papillary cancers, but coexisting follicular cancers have also been reported. Nearly 10 percent of patients with Hürthle cell cancers have foci of anaplastic cancer within the Hürthle cell cancer [
         <a href="#rid14">
          14
         </a>
         ]. In addition, transformation from differentiated to anaplastic cancer has been described in a patient who was followed with serial biopsies [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         These findings lend support to the hypothesis that anaplastic cancer develops from more differentiated tumors as a result of one or more dedifferentiating events [
         <a href="#rid16">
          16
         </a>
         ]. Since activating mutations in
         <em>
          BRAF
         </em>
         and RAS are seen in both well-differentiated thyroid malignancies and anaplastic thyroid cancer, these are presumed to be early events in the progression pathway [
         <a href="#rid17">
          17
         </a>
         ]. Late events that are seen more commonly in the anaplastic tumor rather than the precursor well-differentiated tumor include mutations in p53 tumor suppressor protein [
         <a href="#rid18">
          18-21
         </a>
         ], 16p [
         <a href="#rid22">
          22
         </a>
         ], catenin (cadherin-associated protein), beta 1, and
         <em>
          PIK3CA
         </em>
         [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Up to one-half of patients have a history of multinodular goiter, and some have a history of partial thyroidectomy for goiter.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Disease presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nearly all patients with anaplastic cancer present with a thyroid mass. However, regional or distant spread is apparent at the time of initial diagnosis in 90 percent of cases [
         <a href="#rid11">
          11-13,24
         </a>
         ]. Sites of regional involvement can include the perithyroidal fat and muscle, lymph nodes, larynx, trachea, esophagus, tonsil, and great vessels of the neck and mediastinum. Distant metastases are found at initial disease presentation in 15 to 50 percent of patients [
         <a href="#rid8">
          8-10,12
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The lungs are the most common site of distant metastases, being involved in up to 90 percent of patients with distant disease [
         <a href="#rid9">
          9,10
         </a>
         ]. These metastases are usually intrapulmonary mass lesions, but pleural involvement can occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Approximately 5 to 15 percent of patients have bone metastases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Five percent have brain metastases, and a few have metastases to the skin, liver, kidneys, pancreas, heart, and adrenal glands [
         <a href="#rid9">
          9-11,25-29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rare patients have no detectable thyroid tumor at the time of diagnosis, presenting with metastatic disease [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Clinical manifestations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms
         </strong>
         – The primary symptom of anaplastic cancer is a rapidly enlarging neck mass, occurring in approximately 85 percent of patients. The enlarging thyroid tumor may cause neck pain and tenderness, and compression (or invasion) of the upper aerodigestive tract, resulting in dyspnea (approximately 35 percent of patients), dysphagia (30 percent), hoarseness (25 percent), and cough (and sometimes hemoptysis, 25 percent). Less common symptoms are chest pain, bone pain, headache, confusion, or abdominal pain from metastases [
         <a href="#rid25">
          25,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Constitutional symptoms can occur, including anorexia, weight loss, fatigue, and fever of unknown origin [
         <a href="#rid30">
          30-33
         </a>
         ]. Rarely, rapid growth of the tumor within the thyroid causes thyroiditis, with symptoms of hyperthyroidism and more severe neck pain and tenderness [
         <a href="#rid25">
          25,34,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination
         </strong>
         – On physical examination, most patients have bilateral but asymmetric thyroid enlargement. The goiter is typically hard and nodular and may be tender. A dominant nodule is often present. Some nodules may be softer and fluctuant, indicating focal tumor necrosis [
         <a href="#rid13">
          13
         </a>
         ]. A few patients have a solitary nodule or a diffuse non-nodular goiter. The goiter is often fixed to the surrounding structures and does not move with swallowing. By the time of presentation, the primary tumor is usually greater than 5 cm in diameter, but exact measurements are often difficult because the borders of the tumor are indistinct.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Approximately 50 percent of patients have enlarged cervical lymph nodes. Other findings of local extension of the disease include stridor, tracheal deviation, vocal cord paralysis due to compression or invasion of the trachea, and venous dilatation and superior vena cava syndrome due to retrosternal tumor growth.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The skin overlying the tumor may be erythematous or even ulcerated, and there may be metastases in the skin of the chest and abdomen [
         <a href="#rid13">
          13,36
         </a>
         ]. Focal neurologic symptoms or signs suggesting brain metastases may also be present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory
         </strong>
         – Most patients have normal serum thyroid hormone and thyroid-stimulating hormone (TSH) concentrations, except for those few patients with tumor-related thyroiditis and hyperthyroidism from presumed rapid tumor growth and concomitant tissue destruction [
         <a href="#rid25">
          25,34,35
         </a>
         ]. Serum thyroglobulin concentrations may be high, most often due to secretion from a coexisting differentiated cancer, rather than the anaplastic cancer. Rare patients have leukocytosis due to tumor secretion of lymphokines [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ultrasound
         </strong>
         – The findings on thyroid ultrasound are not specific for anaplastic thyroid cancer. Ultrasonography cannot distinguish benign from malignant intrathyroidal tumors (both tend to be hypoechoic). However, detection of extrathyroidal invasion can provide support for the diagnosis of cancer. Ultrasonography of the neck also can accurately identify involvement of local and regional nodes. (See
         <a class="medical medical_review" href="/z/d/html/7859.html" rel="external">
          "Overview of the clinical utility of ultrasonography in thyroid disease", section on 'Criteria for identifying cancer'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         We agree with the American Thyroid Association (ATA) guidelines that note while fine-needle aspiration (FNA) cytology can yield important diagnostic information, a core biopsy may be necessary to firmly establish the diagnosis and to obtain adequate material for molecular testing and immunostaining [
         <a href="#rid39">
          39
         </a>
         ]. Evaluation of the biopsy material should include routine light microscopy and analysis with immunohistochemistry  (
         <a class="graphic graphic_table graphicRef88072" href="/z/d/graphic/88072.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Molecular testing'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7890.html" rel="external">
          "Diagnostic approach to and treatment of thyroid nodules"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7889.html" rel="external">
          "Thyroid biopsy"
         </a>
         .)
        </p>
        <p>
         The diagnosis of anaplastic cancer is usually established by cytologic examination of cells obtained by FNA biopsy [
         <a href="#rid40">
          40,41
         </a>
         ] and/or of tissue obtained by large-needle or surgical biopsy [
         <a href="#rid42">
          42
         </a>
         ]. Sometimes the diagnosis is made only after surgery is done for what was thought to be a poorly differentiated or occasionally a well-differentiated tumor. Differentiation of anaplastic and poorly differentiated thyroid cancer may be difficult in some patients. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         On cytopathology, morphologic patterns of anaplastic thyroid cancer include spindle cell, pleomorphic giant cell, and/or squamoid [
         <a href="#rid9">
          9
         </a>
         ]. Many anaplastic thyroid cancers have a mixed morphology of two or all three patterns. One common mixed morphologic type is biphasic spindle and giant cell tumor  (
         <a class="graphic graphic_picture graphicRef88833" href="/z/d/graphic/88833.html" rel="external">
          picture 1
         </a>
         ). Numerous mitotic figures and atypical mitoses are present  (
         <a class="graphic graphic_picture graphicRef88832" href="/z/d/graphic/88832.html" rel="external">
          picture 2
         </a>
         ). There is typically extensive necrosis. Unlike differentiated thyroid cancer, anaplastic thyroid cancer cells are much less likely to stain positive for thyroid transcription factor 1
         <em>
          (TTF1
         </em>
         ) or PAX-8 and do not stain positive for thyroglobulin in the anaplastic component of the tumor (may see thyroglobulin staining in the associated more well-differentiated component of the tumor)  (
         <a class="graphic graphic_table graphicRef88072" href="/z/d/graphic/88072.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7823.html" rel="external">
          "Atlas of thyroid cytopathology", section on 'Anaplastic'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29674060">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other malignancies that may look histologically similar to anaplastic thyroid cancer but have significantly different treatment and prognosis include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poorly differentiated thyroid cancer. (See
         <a class="medical medical_review" href="/z/d/html/7819.html" rel="external">
          "Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer", section on 'Anaplastic and poorly differentiated thyroid cancer'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medullary thyroid cancer. (See
         <a class="medical medical_review" href="/z/d/html/7848.html" rel="external">
          "Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphoma. (See
         <a class="medical medical_review" href="/z/d/html/7823.html" rel="external">
          "Atlas of thyroid cytopathology", section on 'Lymphoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Melanoma. (See
         <a class="medical medical_review" href="/z/d/html/4843.html" rel="external">
          "Pathologic characteristics of melanoma", section on 'Histopathologic diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sarcoma. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Histopathology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Differentiation of anaplastic and poorly differentiated thyroid cancer may be difficult in some patients with anaplastic thyroid cancer who have coexisting poorly differentiated (or well-differentiated) thyroid cancer. Careful attention to morphology and immunohistochemical studies  (
         <a class="graphic graphic_table graphicRef88072" href="/z/d/graphic/88072.html" rel="external">
          table 1
         </a>
         ) is required to distinguish anaplastic thyroid cancer from poorly differentiated thyroid cancer and other malignancies.
        </p>
        <p>
         The differential diagnosis in a patient presenting with a neck mass is extensive and varies with the age of the patient at presentation. Although the majority of these masses represent benign thyroid nodules and cysts or differentiated thyroid cancer, a rapidly growing neck mass is concerning for anaplastic thyroid cancer or primary lymphoma of the thyroid (see
         <a class="medical medical_review" href="/z/d/html/7890.html" rel="external">
          "Diagnostic approach to and treatment of thyroid nodules"
         </a>
         ). Neck masses that are not of thyroidal origin may be congenital (ie, vascular anomaly), inflammatory (lymph node enlargement), or other neoplastic (primary or metastatic disease) disorders. The differential diagnosis of a neck mass is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6857.html" rel="external">
          "Differential diagnosis of a neck mass"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2187238">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients diagnosed with anaplastic thyroid cancer on the basis of the findings on cytopathology, further evaluation should include laboratory evaluation, imaging studies, and testing for
         <em>
          BRAF
         </em>
         V600E mutation [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3225632535">
         <span class="h2">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with anaplastic thyroid cancer should undergo evaluation of the airway and vocal cords. Some patients may require emergency intervention to secure the airway or avert impending neurovascular compromise.
        </p>
        <p class="headingAnchor" id="H6357864">
         <span class="h2">
          Laboratory evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         We typically measure:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroid function tests (TSH, free thyroxine [T4]), if not previously measured
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrolytes, blood urea nitrogen (BUN), creatinine, glucose, and liver function tests
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum calcium and phosphorus (to assess for hypercalcemia of malignancy or hypocalcemia due to compromise of the parathyroid glands secondary to invading anaplastic thyroid cancer)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum thyroglobulin
        </p>
        <p>
        </p>
        <p>
         We measure serum thyroglobulin as part of the initial evaluation to assess for the possibility of metastatic well-differentiated thyroid cancer (20 to 30 percent of patients with anaplastic thyroid cancer have coexisting differentiated thyroid cancer) and to assist in determining if the metastatic lesions are from the well-differentiated component of the tumor (rather than anaplastic metastatic sites). In patients with metastatic differentiated thyroid cancer, the thyroglobulin level is markedly elevated, whereas it should be normal in patients with anaplastic thyroid cancer. Elevated serum thyroglobulin can also be seen in nodular thyroid disease and goiter. (See
         <a class="medical medical_review" href="/z/d/html/2193.html" rel="external">
          "Differentiated thyroid cancer: Role of serum thyroglobulin"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Appropriate imaging is critical for defining the extent of disease, planning therapy, and monitoring the response to treatment. We typically obtain the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ultrasound of the neck (if not already performed)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Positron emission tomography (PET)/computed tomography (CT) using 18F-fluorodeoxyglucose (18FDG; neck to pelvis)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brain magnetic resonance imaging (MRI) or CT
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skeletal radiographs if bony metastases are present (radiographs typically show lytic lesions)
        </p>
        <p>
        </p>
        <p>
         If PET/CT scanning is not readily available, cross-sectional imaging of the brain, neck, chest, abdomen, and pelvis with CT or MRI provides adequate initial staging information.
        </p>
        <p>
         PET/CT scan is being used with increasing frequency to evaluate and monitor patients with anaplastic thyroid cancer [
         <a href="#rid43">
          43
         </a>
         ]. Compared with differentiated thyroid cancer, anaplastic cancer is very hypermetabolic with intense uptake of 18FDG in the primary thyroid tumor, cervical and mediastinal lymph nodes, and in distant metastases [
         <a href="#rid44">
          44-47
         </a>
         ].
        </p>
        <p>
         CT of the neck and mediastinum can accurately delineate the extent of the thyroid tumor and identify tumor invasion of the great vessels and upper aerodigestive tract [
         <a href="#rid48">
          48
         </a>
         ]. Typical findings include masses that are isodense or slightly hyperdense relative to skeletal muscle, dense calcifications, and areas of necrosis  (
         <a class="graphic graphic_diagnosticimage graphicRef79632" href="/z/d/graphic/79632.html" rel="external">
          image 1
         </a>
         ). MRI is similarly useful for defining the local extent of disease and for identifying distant metastases [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H395868763">
         <span class="h2">
          Molecular testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         We perform a rapid test for
         <em>
          BRAF V600E
         </em>
         mutations as quickly as possible (using immunohistochemical staining on FNA or core biopsy samples with an antibody specific for the BRAF V600E-mutated protein) so as not to delay treatment [
         <a href="#rid51">
          51
         </a>
         ]. In addition, next-generation molecular sequencing (if available) should be performed to evaluate for the presence of other targetable mutations that might be able to be treated in the context of a clinical trial (preferred), through standard of care, or through a compassionate use program. Promising targets that are seen in anaplastic thyroid cancer and should be included in the evaluation include, at the minimum,
         <em>
          BRAF
         </em>
         ,
         <em>
          TSC1
         </em>
         ,
         <em>
          TSC2
         </em>
         ,
         <em>
          ALK
         </em>
         fusion genes,
         <em>
          NTRK
         </em>
         fusion genes, and
         <em>
          RET
         </em>
         fusion genes. (See
         <a class="local">
          'Our approach to treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H6358271">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rarely, fine-needle biopsy of distant metastatic sites is required to differentiate anaplastic from differentiated thyroid cancer. In patients with surgically resectable disease, biopsy of distant metastases can be performed after completion of primary surgery [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Patients with anaplastic thyroid cancer who present with a rapidly growing neck mass and voice hoarseness require evaluation by an otolaryngologist/head and neck surgeon to assess for vocal cord function, airway invasion, and resectability.
        </p>
        <p class="headingAnchor" id="H3574110">
         <span class="h1">
          STAGING
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) have adopted the eighth (2017) TNM (tumor, node, metastasis) classification system  (
         <a class="graphic graphic_table graphicRef110635" href="/z/d/graphic/110635.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid52">
          52
         </a>
         ]. In the updated staging system, the T category follows the same definitions as those used for differentiated thyroid cancers, rather than classifying all anaplastic thyroid cancer as T4 disease. (See
         <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">
          "Differentiated thyroid cancer: Clinicopathologic staging", section on 'TNM system'
         </a>
         .)
        </p>
        <p>
         All anaplastic cancers are considered stage IV cancers [
         <a href="#rid53">
          53
         </a>
         ]. Intrathyroidal anaplastic cancers are designated IVA, whereas anaplastic cancers with gross extrathyroidal extension or cervical lymph node metastases are IVB and with distant metastases IVC.
        </p>
        <p class="headingAnchor" id="H15939925">
         <span class="h1">
          OUR APPROACH TO TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Selection of initial therapy is guided by stage of disease and results of molecular testing (if available)  (
         <a class="graphic graphic_algorithm graphicRef130965" href="/z/d/graphic/130965.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Molecular testing'
         </a>
         above.)
        </p>
        <p>
         The following approach, which is largely consistent with the American Thyroid Association (ATA) and the National Comprehensive Cancer Network (NCCN) guidelines for management of patients with anaplastic thyroid cancer [
         <a href="#rid39">
          39,54
         </a>
         ], is based upon case series and clinical experience. Because this is a rare tumor and many of the patients may be elderly and/or have significant symptoms related to the disease that may affect their performance status, accruing patients to large clinical studies is very difficult but should be a priority.
        </p>
        <p class="headingAnchor" id="H1866479099">
         <span class="h2">
          <i>
           BRAF
          </i>
          V600E mutation identified
         </span>
        </p>
        <p class="headingAnchor" id="H2548483443">
         <span class="h3">
          Stage IVA
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who present with resectable tumors, we suggest complete resection followed by combined chemotherapy and radiation  (
         <a class="graphic graphic_algorithm graphicRef130965" href="/z/d/graphic/130965.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3319363284">
         <span class="h4">
          Extent of surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with an intrathyroidal anaplastic cancer, we suggest total thyroidectomy (if it can be done with complete gross resection of tumor and minimal morbidity) rather than lobectomy. The rationale for this is that differentiated thyroid cancer and anaplastic thyroid cancer often coexist, and total thyroidectomy offers a greater chance of complete resection, which facilitates subsequent treatment with radioiodine of the accompanying differentiated thyroid cancer. For the rare patients with intrathyroidal anaplastic thyroid cancer, without a coexistent well-differentiated thyroid cancer component, thyroid lobectomy with wide margins of adjacent soft tissue on the side of the tumor is an appropriately aggressive alternative surgical approach.
        </p>
        <p>
         In a systematic review of surgery in anaplastic thyroid cancer (stage IVA 10 percent, IVB 48 percent, and IVC 36 percent), median survival was 6.6 months in patients undergoing primary surgery and 2.1 months for nonsurgical patients [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3270877152">
         <span class="h4">
          Chemoradiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         At Memorial Sloan Kettering Cancer Center (MSKCC) and other centers, intensity-modulated radiation therapy (IMRT) is given in combination with chemotherapy [
         <a href="#rid56">
          56,57
         </a>
         ]. A randomized phase II study through the Radiation Therapy Oncology Group for anaplastic thyroid cancer was completed using IMRT with a total dose of 66 Gy in 33 daily fractions [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         At MSKCC, a total dose of 70 Gy to gross tumor is used, 60 to 66 Gy to the postoperative bed, and 50 to 54 Gy to potential microscopic residual disease regions with standard daily fractionation. The dose of radiation can change if clinically indicated.
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          Doxorubicin
         </a>
         20 mg/m
         <sup>
          2
         </sup>
         weekly or
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         50 mg/m
         <sup>
          2
         </sup>
         weekly is used throughout the radiation course but there are other reasonable regimens described in the literature [
         <a href="#rid59">
          59-62
         </a>
         ].
        </p>
        <p>
         There are very little data about the optimal chemotherapy to be used with radiation therapy for anaplastic thyroid cancer. The majority of the data includes either anthracyclines [
         <a href="#rid56">
          56,63
         </a>
         ], taxanes [
         <a href="#rid61">
          61,64,65
         </a>
         ], or even the combination of both [
         <a href="#rid57">
          57,66
         </a>
         ].
        </p>
        <p>
         As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study, 37 patients were treated with weekly
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         (10 mg/m
         <sup>
          2
         </sup>
         ) with hyperfractionated radiation therapy (given three days per week) for a median total dose of 5760 cGy [
         <a href="#rid56">
          56
         </a>
         ]. Median survival was six months with 28 percent alive at one year. The median locoregional, progression-free survival was 10.1 months. Older patients (≥70 years) had worse outcomes than younger patients, with 60 percent dying in the first three months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another study evaluated a more intensive regimen combining surgery (if possible) with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (120 mg/m
         <sup>
          2
         </sup>
         ) and
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         (60 mg/m
         <sup>
          2
         </sup>
         ), both before and after hyperfractionated radiation therapy [
         <a href="#rid59">
          59
         </a>
         ]. For 30 patients, median survival was 10 months and three-year survival was 27 percent.
        </p>
        <p>
        </p>
        <p>
         Although these reports support a possible survival advantage for combined modality therapy (combining radiation and chemotherapy), selection bias is a major confounding factor in determining the effect of treatment on outcome. Patients who undergo resection followed by adjuvant therapy often have less extensive disease. The optimal timing of the individual components and the selection of chemotherapy regimen are uncertain.
        </p>
        <p>
         Randomized controlled trials are not available to definitively prove benefit for combined modality therapy. Thus, there are no standard regimens. However, the use of weekly
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         (10 mg/m
         <sup>
          2
         </sup>
         ) concurrently with radiation therapy is both reasonable and commonly applied [
         <a href="#rid56">
          56
         </a>
         ], while more aggressive regimens have combined
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         and doxorubicin [
         <a href="#rid62">
          62
         </a>
         ] or
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and doxorubicin [
         <a href="#rid59">
          59
         </a>
         ] with radiation. Given the overall poor prognosis of current treatment modalities, consideration should always be given to referring a patient with anaplastic cancer for participation in a clinical trial.
        </p>
        <p>
         The addition of
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         to combined modality therapy (eg, concurrent
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         and IMRT) did not improve survival outcomes compared with the addition of placebo in 89 patients with anaplastic thyroid cancer (stage IVA to IVC) [
         <a href="#rid58">
          58
         </a>
         ]. However, in an unplanned, post hoc analysis, the one-year overall survival favored the pazopanib arm (37.1 versus 29 percent), with the strongest benefit in patients without metastatic disease at presentation.
        </p>
        <p class="headingAnchor" id="H3755689374">
         <span class="h3">
          Stage IVB
         </span>
         <span class="headingEndMark">
          —
         </span>
         If a
         <em>
          BRAF
         </em>
         V600E mutation is present, we initiate neoadjuvant
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         (150 mg twice daily) plus
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         (2 mg daily) to improve the chance of complete tumor resection  (
         <a class="graphic graphic_algorithm graphicRef130965" href="/z/d/graphic/130965.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid67">
          67,68
         </a>
         ]. If initial surgery is going to be attempted without neoadjuvant dabrafenib plus trametinib in a patient whose scans suggest resectable disease, it should be performed by an experienced thyroid cancer surgeon with the understanding that surgery should be stopped early if the chance for morbidity is high.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Resectable
         </strong>
         – If the response to
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         plus
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         is favorable and disease is considered resectable, complete resection should be attempted, as long as gross tumor resection can be achieved with minimal morbidity. For patients with locally advanced disease, the extent of surgery depends upon the degree of soft tissue involvement. Options include total thyroidectomy, lobectomy with wide margins of adjacent soft tissue, or en bloc resection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with resectable disease, surgery is followed with chemoradiation as described for stage IVA (see
         <a class="local">
          'Stage IVA'
         </a>
         above). Some patients have prolonged survival (&gt;2 years) with surgery combined with postoperative adjuvant chemoradiation [
         <a href="#rid6">
          6,11,69,70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unresectable
         </strong>
         – If disease remains unresectable,
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         plus
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         can be continued if associated with disease stability or improvement. If the response is not favorable, alternative management options include chemoradiation (see
         <a class="local">
          'Chemoradiation'
         </a>
         above), clinical trials, or best supportive care.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In nonrandomized small studies, improvements in outcomes with
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         plus
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         have been reported in a few cases [
         <a href="#rid67">
          67,71-73
         </a>
         ]. In a study of dabrafenib and trametinib in rare
         <em>
          BRAF
         </em>
         mutant tumors, 36 patients had unresectable or metastatic anaplastic thyroid cancer with the
         <em>
          BRAF
         </em>
         V600E mutation [
         <a href="#rid74">
          74
         </a>
         ]. The complete and partial response rates were 6 and 47 percent, respectively, with a 12- and 24-month progression-free survival rate of 43.2 and 27.0 percent, respectively [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In another small study in patients with
         <em>
          BRAF
         </em>
         -mutated anaplastic thyroid cancer who were treated with the BRAF inhibitor,
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         , there was a 29 percent response rate [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3193556027">
         <span class="h3">
          Stage IVC
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no curative therapy for metastatic anaplastic thyroid cancer, and the disease is uniformly fatal. In one case series, the median survival in patients with anaplastic thyroid cancer with distant metastases at the time of initial diagnosis was 4.2 months, compared with 6 months in those without metastases [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4244898944">
         <span class="h4">
          Active therapy preferred
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who present with metastatic disease who desire active therapy (rather than palliative care), enrollment in clinical trials of BRAF-targeted therapy (based on molecular testing) is strongly encouraged  (
         <a class="graphic graphic_algorithm graphicRef130965" href="/z/d/graphic/130965.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Molecular testing'
         </a>
         above.)
        </p>
        <p>
         If clinical trials are not available, we suggest
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         plus
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         in tumors with a
         <em>
          BRAF
         </em>
         mutation. Surgical resection for residual tumor can be considered if the disease is responsive [
         <a href="#rid59">
          59,69
         </a>
         ]. If resectable, surgery should then be followed by re-initiation of dabrafenib plus trametinib if the distant metastases are stable or improved during prior therapy [
         <a href="#rid71">
          71,73
         </a>
         ]. If not resectable, we continue dabrafenib plus trametinib if we are seeing an otherwise favorable response to therapy. If the response to dabrafenib plus trametinib is not favorable, options include chemoradiation, clinical trials, or best supportive care. If a patient's performance status is adequate, participation in a clinical study is strongly recommended. If a clinical study is not available, and a patient seems to be a good candidate to receive systemic therapy after progression on dabrafenib and trametinib, we would follow a similar approach as noted below when there is no targetable mutation. (See
         <a class="local">
          'Another targetable mutation absent or unknown'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2010704938">
         <span class="h4">
          End-of-life care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the very rapid course of disease progression and the poor treatment outcomes, end-of-life issues and plans for comfort care measures are an integral part of disease management planning for all patients with anaplastic thyroid cancer, especially for patients with stage IVB or IVC disease [
         <a href="#rid39">
          39
         </a>
         ]. Palliative and end-of-life care issues are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2196.html" rel="external">
          "Approach to symptom assessment in palliative care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14238.html" rel="external">
          "Assessment and management of dyspnea in palliative care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2199.html" rel="external">
          "Overview of managing common non-pain symptoms in palliative care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2883045368">
         <span class="h2">
          <i>
           BRAF
          </i>
          V600E mutation not identified or unknown
         </span>
        </p>
        <p class="headingAnchor" id="H1878591281">
         <span class="h3">
          Stage IVA or resectable IVB disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with tumor localized to the thyroid or if locoregional disease is resectable, complete resection should be attempted, as long as gross tumor resection can be achieved with minimal morbidity  (
         <a class="graphic graphic_algorithm graphicRef130965" href="/z/d/graphic/130965.html" rel="external">
          algorithm 1
         </a>
         ). After complete resection, some patients have prolonged survival (&gt;2 years), often in conjunction with postoperative adjuvant chemoradiation [
         <a href="#rid6">
          6,11,55,69,70
         </a>
         ]. (See
         <a class="local">
          'Stage IVA'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2418514062">
         <span class="h3">
          Stage IVB (unresectable) or IVC disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with unresectable locoregional or metastatic disease, options include systemic therapy, chemoradiation (see
         <a class="local">
          'Chemoradiation'
         </a>
         above), or supportive care depending on the clinical setting.
        </p>
        <p class="headingAnchor" id="H2423979888">
         <span class="h4">
          Another targetable mutation present
         </span>
         <span class="headingEndMark">
          —
         </span>
         If another targetable mutation is present, enrollment in a clinical trial of mutation-directed therapy is preferred. Specific inhibitors of oncogenic
         <em>
          ALK
         </em>
         ,
         <em>
          NTRK
         </em>
         , or
         <em>
          RET
         </em>
         fusion mutations can be considered for unresectable stage IVB or IVC disease, preferably within the context of a clinical trial, although the use of NTRK or RET inhibitors are US Food and Drug Administration (FDA) approved for this indication.
        </p>
        <p>
         Significant activity in metastatic disease has been shown in anaplastic thyroid cancer with
         <em>
          NTRK
         </em>
         fusion genes [
         <a href="#rid77">
          77,78
         </a>
         ] and
         <em>
          RET
         </em>
         fusion genes [
         <a href="#rid79">
          79
         </a>
         ] (although all studies have been small and, in some cases, equivalent to case reports). Other potential targets include
         <em>
          TSC1
         </em>
         /
         <em>
          TSC2
         </em>
         mutations [
         <a href="#rid80">
          80
         </a>
         ] and
         <em>
          ALK
         </em>
         fusion genes [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
         Mutation-specific kinase inhibitor regimens include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Larotrectinib
         </strong>
         <strong>
          or
         </strong>
         <strong>
          entrectinib
         </strong>
         <strong>
          (
         </strong>
         <strong>
          <em>
           NTRK
          </em>
         </strong>
         <strong>
          gene fusion)
         </strong>
         –
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          Larotrectinib
         </a>
         and
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         , highly selective inhibitors of TRK kinases, have been FDA approved for treatment of any solid tumor bearing an
         <em>
          NTRK
         </em>
         1-3 fusion mutation, including anaplastic thyroid cancer [
         <a href="#rid82">
          82,83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selpercatinib
         </strong>
         <strong>
          or
         </strong>
         <strong>
          pralsetinib
         </strong>
         <strong>
          (
         </strong>
         <strong>
          <em>
           RET
          </em>
         </strong>
         <strong>
          fusion)
         </strong>
         –
         <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">
          Selpercatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="129470" href="/z/d/drug information/129470.html" rel="external">
          pralsetinib
         </a>
         are oral kinase inhibitors that selectively target RET kinase. They have been approved by the FDA for the treatment of advanced or metastatic
         <em>
          RET
         </em>
         fusion-positive thyroid cancer,
         <em>
          RET
         </em>
         -mutant medullary thyroid cancer, and other types of cancers which have an alteration (mutation or fusion) in the
         <em>
          RET
         </em>
         gene [
         <a href="#rid79">
          79,84
         </a>
         ]. In the clinical study, activity was seen in anaplastic thyroid cancer with a
         <em>
          RET
         </em>
         fusion gene [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – A prolonged response was reported in a phase II study with
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         in a patient with anaplastic thyroid cancer containing a
         <em>
          TSC2
         </em>
         mutation [
         <a href="#rid80">
          80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7819.html" rel="external">
          "Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer", section on 'Anaplastic and poorly differentiated thyroid cancer'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Considering that high expression of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) in anaplastic thyroid cancer [
         <a href="#rid85">
          85
         </a>
         ], immunotherapy may be a promising approach. There have been several promising small studies of immunotherapy alone or in combination with other agents [
         <a href="#rid86">
          86-89
         </a>
         ], but these still need to be better evaluated. Many studies are in progress, evaluating if there is activity with immunotherapy in metastatic anaplastic thyroid cancer. However, there are concerns about the safety of using immunotherapy with radiation therapy in anaplastic thyroid cancer [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3786444332">
         <span class="h4">
          Another targetable mutation absent or unknown
         </span>
         <span class="headingEndMark">
          —
         </span>
         If a targetable mutation is absent or testing is unavailable, options include chemoradiation (see
         <a class="local">
          'Chemoradiation'
         </a>
         above) followed by observation or clinical trials.
        </p>
        <p>
         In patients who would otherwise be eligible for systemic therapy but do not have a clinical trial available, there are other reasonable options, but they are all based on fairly small, single studies and the lack of extensive data needs to be considered in discussion with the patient.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytotoxic chemotherapy
         </strong>
         – There are some data to support the use of cytotoxic chemotherapy. As an example, in a randomized trial comparing combination
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         versus doxorubicin alone, the complete response rate was higher in the combination group (3 of 18 patients [17 percent] compared with none of 21 patients in the doxorubicin group) [
         <a href="#rid90">
          90
         </a>
         ].
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          Paclitaxel
         </a>
         as a single agent has been reported to have a response rate of 53 percent [
         <a href="#rid91">
          91
         </a>
         ]. We have not seen such responses to either of these approaches; however, both of these regimens are reasonable to consider.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunotherapy
         </strong>
         – The Anaplastic Thyroid Carcinoma
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          Lenvatinib
         </a>
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          Pembrolizumab
         </a>
         (ATLEP) study evaluated the combination of lenvatinib and pembrolizumab in both anaplastic and poorly differentiated thyroid cancer [
         <a href="#rid92">
          92
         </a>
         ]. In 27 patients with anaplastic thyroid cancer, 51.9 percent of patients had a partial response. The median progression-free survival was reported to be 9.5 months and median overall survival was 10.25 months. A single institution study of
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         and
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         in anaplastic thyroid cancer reported partial responses in 3 of 10 patients [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In patients with advanced disease who do not desire or who are not eligible for systemic therapy, palliation of symptoms is a high priority [
         <a href="#rid39">
          39
         </a>
         ]. Treatment should be directed toward securing the airway and ensuring access for nutritional support. Locoregional resection may be necessary for palliation of airway or esophageal obstruction. However, death is usually attributable to upper airway obstruction and suffocation (often despite tracheostomy) in 50 to 60 percent of patients and to a combination of complications of local and distant disease in the remainder [
         <a href="#rid11">
          11,93
         </a>
         ]. For patients with bone metastases, palliative radiotherapy may be beneficial in improving pain. (See
         <a class="local">
          'End-of-life care'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3575237">
         <span class="h1">
          MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who respond to initial management (M0 disease) require surveillance for recurrence. There is no known role for adjuvant therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – We typically obtain chest CT at four weeks and a single positron emission tomography (PET)/CT scan at three months after the completion of chemoradiation therapy [
         <a href="#rid45">
          45
         </a>
         ]. Thereafter, we monitor with CT scans (with contrast) of the neck, chest, and abdomen (including adrenal glands) every one to three months for the first 24 months and then less frequently (every 4 to 12 months) thereafter. Brain imaging during the first three months after treatment is recommended with a low threshold of repeating if concerning symptoms develop. Other imaging studies should be based upon clinical symptoms that develop during follow-up. The benefit of continued imaging after four years is questionable, although annual imaging of the neck and chest are reasonable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Radioactive iodine has no role in the primary treatment of anaplastic thyroid cancer. However, radioactive iodine scanning/ablation/therapy should be considered in survivors, one to two years after initial therapy, if a significant component of the original tumor was well differentiated or if the serum thyroglobulin level remains inappropriately elevated during follow-up. (See
         <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">
          "Differentiated thyroid cancer: Radioiodine treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thyroid hormone replacement
         </strong>
         – Patients who have total thyroidectomy require thyroid hormone therapy to replace normal thyroid hormone production. T4 (approximately 1.6 mcg/kg of body weight) should be started immediately after surgery. The adequacy of therapy should be evaluated clinically and by measurement of serum TSH in one month. The goal of T4 therapy should be to restore and maintain euthyroidism; suppression of serum TSH concentrations to less than normal is not indicated, unless for treatment of coexisting differentiated thyroid cancer. (See
         <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">
          "Differentiated thyroid cancer: Surgical treatment", section on 'Postoperative thyroid hormone therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2187296">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anaplastic thyroid cancers are extremely aggressive, with a disease-specific mortality approaching 100 percent. The median survival from diagnosis ranges from three to seven months, and the one- and five-year survival rates are 20 to 35 percent and 5 to 14 percent, respectively [
         <a href="#rid11">
          11,12,24,69,94-96
         </a>
         ], although many feel that these estimates are overly optimistic. In a review of published case series (1771 patients treated between 1949 and 2007), the median survival was five months, and the one-year survival was 20 percent [
         <a href="#rid4">
          4
         </a>
         ]. Several important prognostic characteristics have been identified. Patients with disease either confined to the thyroid or with only local and regional metastases survive longer than those with distant metastases [
         <a href="#rid6">
          6,8,10,97
         </a>
         ]. Tumor size also appears to be important. In one study, as an example, the two-year survival was 25 versus 3 to 15 percent in patients with tumors less than 6 cm versus larger than 6 cm in maximum dimension [
         <a href="#rid8">
          8,11
         </a>
         ].
        </p>
        <p>
         Other variables that may predict a worse prognosis include older age at diagnosis, male sex, and dyspnea as a presenting symptom [
         <a href="#rid6">
          6,8-11,94,97,98
         </a>
         ]. Patients who were previously treated for differentiated cancer and subsequently developed anaplastic cancer have outcomes similar to those without an antecedent cancer [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p>
         Relatively favorable prognostic factors include unilateral tumor, diameter of less than 5 cm, and the absence of extrathyroidal invasion or cervical lymph node involvement.
        </p>
        <p>
         The use of targeted therapy will likely change the overall median survival rates. (See
         <a class="local">
          'BRAF V600E mutation identified'
         </a>
         above and
         <a class="local">
          'Another targetable mutation present'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3414725054">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113808.html" rel="external">
          "Society guideline links: Thyroid nodules and cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – The primary symptom of anaplastic cancer is a rapidly enlarging neck mass, occurring in approximately 85 percent of patients. Approximately 20 percent of patients have a history of differentiated thyroid cancer, and 20 to 30 percent have a coexisting differentiated cancer. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of anaplastic cancer is usually established by cytologic examination of cells obtained by fine-needle aspiration (FNA) biopsy and/or of tissue obtained by large-needle or surgical biopsy. Evaluation of the biopsy material should include routine light microscopy and analysis with immunohistochemistry  (
         <a class="graphic graphic_table graphicRef88072" href="/z/d/graphic/88072.html" rel="external">
          table 1
         </a>
         ). On cytopathology, morphologic patterns of anaplastic thyroid cancer include spindle cell, pleomorphic giant cell, and/or squamoid  (
         <a class="graphic graphic_picture graphicRef88833" href="/z/d/graphic/88833.html" rel="external">
          picture 1
         </a>
         ). Many anaplastic thyroid cancers have a mixed morphology of two or all three patterns. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Other malignancies that may look histologically similar to anaplastic thyroid cancer but have significantly different treatment and prognosis include poorly differentiated thyroid cancer, medullary thyroid cancer, lymphoma, melanoma, and sarcoma. Careful attention to morphology and immunohistochemical studies  (
         <a class="graphic graphic_table graphicRef88072" href="/z/d/graphic/88072.html" rel="external">
          table 1
         </a>
         ) are required to distinguish anaplastic thyroid cancer from poorly differentiated thyroid cancer and other malignancies. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory testing
         </strong>
         – For patients diagnosed with anaplastic thyroid cancer on the basis of the findings on cytopathology, we obtain the following laboratory tests: thyroid-stimulating hormone [TSH], free thyroxine [T4], thyroglobulin, complete blood count, electrolytes, blood urea nitrogen [BUN], creatinine, glucose, liver function tests, calcium, and phosphorus. (See
         <a class="local">
          'Laboratory evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Imaging
         </strong>
         – Initial imaging to determine extent of disease should include ultrasound of the neck (if not already performed), positron emission tomography (PET)/CT using 18 F-fluorodeoxyglucose (18FDG; neck to pelvis), and brain MRI or CT. If PET/CT scanning is not readily available, cross-sectional imaging of the brain, neck, chest, abdomen, and pelvis with CT or MRI provides adequate initial staging information. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Molecular testing
         </strong>
         – All tumors should be evaluated for the presence of a
         <em>
          BRAF
         </em>
         mutation as quickly as possible after the diagnosis (using immunohistochemical staining on FNA or core biopsy samples with an antibody specific for the BRAF V600E-mutated protein)  (
         <a class="graphic graphic_algorithm graphicRef130965" href="/z/d/graphic/130965.html" rel="external">
          algorithm 1
         </a>
         ). If available, next-generation molecular sequencing of the cancer should be performed to evaluate for the presence of other targetable mutations that might be able to be treated. Promising and approved targets that are seen in anaplastic thyroid cancer and should be included in the evaluation include
         <em>
          BRAF
         </em>
         ,
         <em>
          TSC1
         </em>
         ,
         <em>
          TSC2
         </em>
         ,
         <em>
          ALK
         </em>
         fusion genes,
         <em>
          RET
         </em>
         fusion genes, and
         <em>
          NTRK
         </em>
         fusion genes. (See
         <a class="local">
          'Molecular testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           BRAF
          </em>
         </strong>
         <strong>
          V600E mutation identified
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Stage IVA
         </strong>
         – For patients who present with resectable tumors  (
         <a class="graphic graphic_algorithm graphicRef130965" href="/z/d/graphic/130965.html" rel="external">
          algorithm 1
         </a>
         ), we suggest complete resection followed by combined modality therapy with chemotherapy and radiation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Stage IVA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For most patients, we suggest total thyroidectomy (if it can be done with complete gross resection of tumor and minimal morbidity) rather than lobectomy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Differentiated thyroid cancer and anaplastic thyroid cancer often coexist, and total thyroidectomy will facilitate subsequent treatment of the differentiated thyroid cancer. However, for the rare patients with intrathyroidal anaplastic thyroid cancer, without a coexistent well-differentiated thyroid cancer component, thyroid lobectomy with wide margins of adjacent soft tissue on the side of the tumor is an appropriately aggressive alternative surgical approach. (See
         <a class="local">
          'Extent of surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Chemotherapy options include
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         , or
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and doxorubicin. (See
         <a class="local">
          'Chemoradiation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Stage IVB or IVC
         </strong>
         – For patients with stage IVB or IVC disease with a
         <em>
          BRAF
         </em>
         V600E mutation  (
         <a class="graphic graphic_algorithm graphicRef130965" href="/z/d/graphic/130965.html" rel="external">
          algorithm 1
         </a>
         ), we suggest
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         plus
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), followed by evaluation for resectability. If the response to dabrafenib plus trametinib is favorable and disease is resectable, resection is followed by chemoradiation for stage IVB disease and re-initiation of dabrafenib plus trametinib for stage IVC disease. If disease remains unresectable, dabrafenib plus trametinib can be continued if associated with disease stability or improvement. If the response is not favorable, alternative management options include chemoradiation, clinical trials, or best supportive care. (See
         <a class="local">
          'Stage IVB'
         </a>
         above and
         <a class="local">
          'Stage IVC'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           BRAF
          </em>
         </strong>
         <strong>
          V600E not identified or unknown
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Stage IVA
         </strong>
         – For patients who present with resectable tumors  (
         <a class="graphic graphic_algorithm graphicRef130965" href="/z/d/graphic/130965.html" rel="external">
          algorithm 1
         </a>
         ), we suggest complete resection followed by combined chemotherapy and radiation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Stage IVA or resectable IVB disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         The extent of thyroid surgery and chemoradiation therapy are the same as for patients with Stage IVA disease with a
         <em>
          BRAF
         </em>
         V600E mutation. (See
         <a class="local">
          'Extent of surgery'
         </a>
         above and
         <a class="local">
          'Chemoradiation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Stage IVB resectable
         </strong>
         – For patients with locally advanced (stage IVB) resectable disease without a
         <em>
          BRAF
         </em>
         V600E mutation  (
         <a class="graphic graphic_algorithm graphicRef130965" href="/z/d/graphic/130965.html" rel="external">
          algorithm 1
         </a>
         ), we suggest surgery (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The extent of surgery depends upon the degree of soft tissue involvement. Options include total thyroidectomy, lobectomy with wide margins of adjacent soft tissue, or en bloc resection. Patients whose tumors are resected completely are treated with chemoradiation. (See
         <a class="local">
          'Stage IVA or resectable IVB disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Stage IVB unresectable or stage IVC
         </strong>
         – For patients with unresectable stage IVB or IVC disease without
         <em>
          a BRAF
         </em>
         V600E mutation, options include targeted therapy (if another targetable mutation is present), chemoradiation, clinical trials, or supportive care, depending on the clinical setting. (See
         <a class="local">
          'Stage IVB (unresectable) or IVC disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         In patients with advanced disease without a targetable mutation, palliation of symptoms is a high priority. Treatment should be directed toward securing the airway and ensuring access for nutritional support. If the patient has a good performance status, enrollment in clinical trials of targeted therapy is strongly encouraged. (See
         <a class="local">
          'Another targetable mutation absent or unknown'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Anaplastic thyroid cancer is almost always rapidly fatal, the few exceptions being patients whose tumors are small and who are treated very aggressively. Palliative/comfort care should be an integral part treatment planning for all patients with anaplastic thyroid cancer, especially for patients with stage IVB or IVC disease. (See
         <a class="local">
          'Prognosis'
         </a>
         above and
         <a class="local">
          'End-of-life care'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008; 37:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke JP, Hay ID, Dignan F, et al. Long-term trends in thyroid carcinoma: a population-based study in Olmsted County, Minnesota, 1935-1999. Mayo Clin Proc 2005; 80:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295:2164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 2010; 22:486.
          </a>
         </li>
         <li class="breakAll">
          SEER Cancer Statistics Review 1975-2009. http://seer.cancer.gov/csr/1975_2009_pops09/results_merged/sect_26_thyroid.pdf (Accessed on February 12, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005; 103:1330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011; 2011:542358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nel CJ, van Heerden JA, Goellner JR, et al. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc 1985; 60:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 1985; 83:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkatesh YS, Ordonez NG, Schultz PN, et al. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990; 66:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan RK, Finley RK 3rd, Driscoll D, et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995; 17:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001; 130:1028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aldinger KA, Samaan NA, Ibanez M, Hill CS Jr. Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 1978; 41:2267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiu AC, Oliveira AA, Schultz PN, et al. Prognostic clinicopathologic features in Hürthle cell neoplasia. Thyroid 1996; 6:S29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore JH Jr, Bacharach B, Choi HY. Anaplastic transformation of metastatic follicular carcinoma of the thyroid. J Surg Oncol 1985; 29:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009; 69:4885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quiros RM, Ding HG, Gattuso P, et al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 2005; 103:2261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura T, Yana I, Kobayashi T, et al. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 1992; 83:1293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992; 52:1369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito T, Seyama T, Mizuno T, et al. Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Jpn J Cancer Res 1993; 84:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moretti F, Farsetti A, Soddu S, et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1997; 14:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komoike Y, Tamaki Y, Sakita I, et al. Comparative genomic hybridization defines frequent loss on 16p in human anaplastic thyroid carcinoma. Int J Oncol 1999; 14:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009; 16:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002; 86:1848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishiyama RH, Dunn EL, Thompson NW. Anaplastic spindle-cell and giant-cell tumors of the thyroid gland. Cancer 1972; 30:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadar T, Mor C, Har-El G, Sidi J. Anaplastic thyroid carcinoma metastatic to the tonsil. J Laryngol Otol 1987; 101:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips DL, Benner KG, Keeffe EB, Traweek ST. Isolated metastasis to small bowel from anaplastic thyroid carcinoma. With a review of extra-abdominal malignancies that spread to the bowel. J Clin Gastroenterol 1987; 9:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murabe H, Akamizu T, Kubota A, Kusaka S. Anaplastic thyroid carcinoma with prominent cardiac metastasis, accompanied by a marked leukocytosis with a neutrophilia and high GM-CSF level in serum. Intern Med 1992; 31:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadar T, Mor C, Shvero J, et al. Anaplastic carcinoma of the thyroid. Eur J Surg Oncol 1993; 19:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lip GY, Jaap AJ, McCruden DC. A presentation of anaplastic carcinoma of the thyroid with symptomatic intra-abdominal metastases. Br J Clin Pract 1992; 46:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glikson M, Feigin RD, Libson E, Rubinow A. Anaplastic thyroid carcinoma in a retrosternal goiter presenting as fever of unknown origin. Am J Med 1990; 88:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanslik T, Gepner P, Franc B, et al. [Anaplastic cancer of the thyroid gland disclosed by prolonged fever or hyperleukocytosis. Two cases]. Ann Med Interne (Paris) 1996; 147:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang TC, Liaw KY, Kuo SH, et al. Anaplastic thyroid carcinoma: review of 24 cases, with emphasis on cytodiagnosis and leukocytosis. Taiwan Yi Xue Hui Za Zhi 1989; 88:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murakami T, Noguchi S, Murakami N, et al. Destructive thyrotoxicosis in a patient with anaplastic thyroid cancer. Endocrinol Jpn 1989; 36:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oppenheim A, Miller M, Anderson GH Jr, et al. Anaplastic thyroid cancer presenting with hyperthyroidism. Am J Med 1983; 75:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barr R, Dann F. Anaplastic thyroid carcinoma metastatic to skin. J Cutan Pathol 1974; 1:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujita T, Ogasawara Y, Naito M, et al. Anaplastic thyroid carcinoma associated with granulocyte colony-stimulating factor: report of a case. Surg Today 2006; 36:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato T, Omura M, Saito J, et al. Neutrophilia associated with anaplastic carcinoma of the thyroid: production of macrophage colony-stimulating factor (M-CSF) and interleukin-6. Thyroid 2000; 10:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid 2021; 31:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eilers SG, LaPolice P, Mukunyadzi P, et al. Thyroid fine-needle aspiration cytology: performance data of neoplastic and malignant cases as identified from 1558 responses in the ASCP Non-GYN Assessment program thyroid fine-needle performance data. Cancer Cytopathol 2014; 122:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jin M, Jakowski J, Wakely PE Jr. Undifferentiated (anaplastic) thyroid carcinoma and its mimics: a report of 59 cases. J Am Soc Cytopathol 2016; 5:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ha EJ, Baek JH, Lee JH, et al. Core needle biopsy could reduce diagnostic surgery in patients with anaplastic thyroid cancer or thyroid lymphoma. Eur Radiol 2016; 26:1031.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogsrud TV, Karantanis D, Nathan MA, et al. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid 2008; 18:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poisson T, Deandreis D, Leboulleux S, et al. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37:2277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control 2005; 12:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen BD, Ram PC. PET/CT staging and posttherapeutic monitoring of anaplastic thyroid carcinoma. Clin Nucl Med 2007; 32:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takashima S, Morimoto S, Ikezoe J, et al. CT evaluation of anaplastic thyroid carcinoma. AJR Am J Roentgenol 1990; 154:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyakoshi A, Dalley RW, Anzai Y. Magnetic resonance imaging of thyroid cancer. Top Magn Reson Imaging 2007; 18:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiacchio S, Lorenzoni A, Boni G, et al. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol 2008; 33:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith AL, Williams MD, Stewart J, et al. Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma. Cancer Cytopathol 2018; 126:406.
          </a>
         </li>
         <li class="breakAll">
          Tuttle RM, Morris LF, Haughen BR, et al. Thyroid - Differentiated and Anaplastic Carcinoma. In: AJCC Cancer Staging Manual, 8th, Amin MB (Ed), Springer, New York 2017. p.873.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2018; 68:55.
          </a>
         </li>
         <li class="breakAll">
          https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf (Accessed on September 02, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu S, Helman SN, Hanly E, Likhterov I. The role of surgery in anaplastic thyroid cancer: A systematic review. Am J Otolaryngol 2017; 38:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherman EJ, Lim SH, Ho AL, et al. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol 2011; 101:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prasongsook N, Foote RL, Molina JR, et al. Impact of aggressive combined-modality primary therapy in anaplastic thyroid carcinoma (ATC): An updated single-institution experience. J Clin Oncol 2014; 32:e17042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherman EJ, Harris J, Bible KC, et al. Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial. Lancet Oncol 2023; 24:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60:1137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987; 60:2372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Troch M, Koperek O, Scheuba C, et al. High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab 2010; 95:E54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011; 21:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levendag PC, De Porre PM, van Putten WL. Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 1993; 26:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beckham TH, Romesser PB, Groen AH, et al. Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. Thyroid 2018; 28:1180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haddad R, Mahadevan A, Posner MR, Sullivan C. Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer. Am J Clin Oncol 2005; 28:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chintakuntlawar AV, Yin J, Foote RL, et al. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. Thyroid 2019; 29:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang JR, Zafereo ME, Dadu R, et al. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid 2019; 29:1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabanillas ME, Ferrarotto R, Garden AS, et al. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid 2018; 28:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haigh PI, Ituarte PH, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001; 91:2335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swaak-Kragten AT, de Wilt JH, Schmitz PI, et al. Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. Radiother Oncol 2009; 92:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol 2018; 36:7.
          </a>
         </li>
         <li class="breakAll">
          https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm606708.htm (Accessed on October 02, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iyer PC, Dadu R, Ferrarotto R, et al. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid 2018; 28:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 2022; 33:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015; 373:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito K, Hanamura T, Murayama K, et al. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck 2012; 34:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waguespack SG, Drilon A, Lin JJ, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 2022; 186:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabanillas ME, Drilon A, Farago AF, et al. 1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer. Ann Oncol 2020; 31:S1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wirth LJ, Sherman E, Robinson B, et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med 2020; 383:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagle N, Grabiner BC, Van Allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 2014; 371:1426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godbert Y, Henriques de Figueiredo B, Bonichon F, et al. Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma. J Clin Oncol 2015; 33:e84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020; 21:271.
          </a>
         </li>
         <li class="breakAll">
          Selpercatinib capsules. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf (Accessed on May 11, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chintakuntlawar AV, Rumilla KM, Smith CY, et al. Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. J Clin Endocrinol Metab 2017; 102:1943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dierks C, Seufert J, Ruf J, et al. 1915P The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: Results from a retrospective study and first results from the prospective phase II ATLEP trial. Ann Oncol 2020; 31:1085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capdevila J, Wirth LJ, Ernst T, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol 2020; 38:2620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorch JH, Barletta JA, Nehs M, et al. A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC). J Clin Oncol 2020; 38:6513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabanillas ME, Dadu R, Ferrarotto R, et al. Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC). J Clin Oncol 2020; 38:6514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56:2155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000; 10:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dierks C, Ruf J, Seufert J, et al. 1646MO Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma. Ann Oncol 2022; 33:S1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tallroth E, Wallin G, Lundell G, et al. Multimodality treatment in anaplastic giant cell thyroid carcinoma. Cancer 1987; 60:1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierie JP, Muzikansky A, Gaz RD, et al. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 2002; 9:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spires JR, Schwartz MR, Miller RH. Anaplastic thyroid carcinoma. Association with differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 1988; 114:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherman SI, Brierley J, Sperling M, Maxon III HR. Initial analysis of staging and outcomes from a prospective multicenter study of treatment of thyroid carcinoma. Thyroid 1996; 6:S39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akslen LA, Haldorsen T, Thoresen SO, Glattre E. Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway. Cancer Res 1991; 51:1234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992; 18:83.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2189 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18502341" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Anaplastic thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15948298" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Long-term trends in thyroid carcinoma: a population-based study in Olmsted County, Minnesota, 1935-1999.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16684987" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Increasing incidence of thyroid cancer in the United States, 1973-2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20418080" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20418080" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15739211" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21772843" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3965822" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2578727" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Anaplastic thyroid carcinoma. A study of 70 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1695118" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7883548" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Anaplastic carcinoma of the thyroid: a 24-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11742333" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Anaplastic thyroid carcinoma: a 50-year experience at a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/657091" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Prognostic clinicopathologic features in Hürthle cell neoplasia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4079403" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Anaplastic transformation of metastatic follicular carcinoma of the thyroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487299" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15880523" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1483945" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1737400" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8100564" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Genetic alterations in thyroid tumor progression: association with p53 gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9038381" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10339673" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Comparative genomic hybridization defines frequent loss on 16p in human anaplastic thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18987168" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12085174" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5040735" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Anaplastic spindle-cell and giant-cell tumors of the thyroid gland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3668379" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Anaplastic thyroid carcinoma metastatic to the tonsil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3680909" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Isolated metastasis to small bowel from anaplastic thyroid carcinoma. With a review of extra-abdominal malignancies that spread to the bowel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1421718" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Anaplastic thyroid carcinoma with prominent cardiac metastasis, accompanied by a marked leukocytosis with a neutrophilia and high GM-CSF level in serum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8270035" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Anaplastic carcinoma of the thyroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1457306" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A presentation of anaplastic carcinoma of the thyroid with symptomatic intra-abdominal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2294770" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Anaplastic thyroid carcinoma in a retrosternal goiter presenting as fever of unknown origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8760694" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : [Anaplastic cancer of the thyroid gland disclosed by prolonged fever or hyperleukocytosis. Two cases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2794956" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Anaplastic thyroid carcinoma: review of 24 cases, with emphasis on cytodiagnosis and leukocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2633916" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Destructive thyrotoxicosis in a patient with anaplastic thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6624779" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Anaplastic thyroid cancer presenting with hyperthyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4377844" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Anaplastic thyroid carcinoma metastatic to skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16378196" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Anaplastic thyroid carcinoma associated with granulocyte colony-stimulating factor: report of a case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11201858" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Neutrophilia associated with anaplastic carcinoma of the thyroid: production of macrophage colony-stimulating factor (M-CSF) and interleukin-6.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33728999" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24913410" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Thyroid fine-needle aspiration cytology: performance data of neoplastic and malignant cases as identified from 1558 responses in the ASCP Non-GYN Assessment program thyroid fine-needle performance data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31042490" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Undifferentiated (anaplastic) thyroid carcinoma and its mimics: a report of 59 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26201291" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Core needle biopsy could reduce diagnostic surgery in patients with anaplastic thyroid cancer or thyroid lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26201291" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Core needle biopsy could reduce diagnostic surgery in patients with anaplastic thyroid cancer or thyroid lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18630999" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20694463" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16258498" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17242574" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : PET/CT staging and posttherapeutic monitoring of anaplastic thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2108546" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : CT evaluation of anaplastic thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17893594" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Magnetic resonance imaging of thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18923370" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Anaplastic thyroid cancer: prevalence, diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29579361" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29579361" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29092098" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29092098" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28366512" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The role of surgery in anaplastic thyroid cancer: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21981877" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Impact of aggressive combined-modality primary therapy in anaplastic thyroid carcinoma (ATC): An updated single-institution experience
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36681089" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15519785" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3664425" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20591979" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21162687" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8482618" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Anaplastic carcinoma of the thyroid gland treated by radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30105947" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15685044" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31595822" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31319771" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29742974" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11413523" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19328572" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29072975" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29072975" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29161986" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35026411" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26287849" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21500309" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35333737" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : 1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32846061" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25295501" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Response and acquired resistance to everolimus in anaplastic thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24687827" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29466156" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31838007" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31838007" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28324060" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : 1915P The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: Results from a retrospective study and first results from the prospective phase II ATLEP trial
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32364844" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : PD-1 Blockade in Anaplastic Thyroid Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3902203" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10958311" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : 1646MO Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2441842" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Multimodality treatment in anaplastic giant cell thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11833496" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3334817" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Anaplastic thyroid carcinoma. Association with differentiated thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Initial analysis of staging and outcomes from a prospective multicenter study of treatment of thyroid carcinoma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1997164" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1582515" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
